Showing results (21-30 of 42) with videos related to
Sort By:
Pageof 5
Hybridoma|January 1, 1984
Production of human monoclonal antibody in mouse ascitesK E Truitt, J W Larrick, A A Raubitschek, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1995
CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinaseK E Truitt, J Shi, S Gibson, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 24, 2014
Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitusJ Rosenstock, K E Truitt, M Baz-Hecht, et al.Oncogene|September 19, 2003
Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1Donna D Eason, Cynthia LeBron, Domenico Coppola, et al.Diabetes, Obesity & Metabolism|June 13, 2012
A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitusH S Chou, K E Truitt, J B Moberly, et al.Echocardiography (Mount Kisco, N.Y.)|May 1, 1996
Nonsurgical Repair of Femoral Artery Pseudoaneurysm with Color Flow Guided Ultrasound Transducer CompressionYun-Ling Feng, Robert E. Truitt, Tina R. Coggins, et al.Journal of Neuroimmunology|April 3, 2012
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patientsJames B Moberly, Daniel M Ford, Hamim Zahir, et al.Journal of Clinical Pharmacology|October 25, 2008
Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulatorShashank Rohatagi, Hamim Zahir, James B Moberly, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 29, 2009
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 DiabetesA B Goldfine, V A Fonseca, M R Jones, et al.Current Medical Research and Opinion|April 8, 2010
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetesKenneth E Truitt, Ronald B Goldberg, Julio Rosenstock, et al.Pageof 5